Market Cap2.05B Stock Price26.72 Revenue$0000 View About CG Oncology CG Oncology is a late-stage clinical biopharmaceutical company developing oncolytic immunotherapies for bladder cancer. The company's product, cretostimogene grenadenorepvec, is an investigational engineered oncolytic immunotherapy designed...
CGON CG Oncology Watchlist 25.860 +1.220+4.95% Close Feb 28 16:00 ET 25.860 0.0000.00% Post 16:41 ET 1.94BMarket Cap-22.18P/E (TTM) 26.015High24.155Low719.16KVolume24.370Open24.640Pre Close18.45MTurnover1.21%Turnover RatioLossP/E (Static)74.93MShares46.99052wk High3.61P/B1.54BFloat Cap24....
CGON CG Oncology Watchlist 26.720 -0.270-1.00% Close Mar 7 16:00 ET 26.720 0.0000.00% Post 16:05 ET 2.00BMarket Cap-22.92P/E (TTM) OverviewOptionsFinancialsAnalysisCompanyNewsCommentsCG Oncology Stock Analyst Ratings & Price Target Analyst Rating Updated: Mar 7, 2025 Based on 5 analysts...
CG Oncology has entered the public market with late-stage clinical trials for its cancer therapy, cretostimogene grenadenorepvec. The company is focused on treating non-muscle-invasive bladder cancer, an area of unmet need due to a shortage of standard treatments. ...
- 《Journal of Clinical Oncology》 被引量: 0发表: 2023年 Designing the Diversity of Canadian Libraries: Excerpts from the CARL Inclusion Perspectives Webinar by Racialized Library Colleagues Five academic librarians from libraries that represent the Canadian Academic Research Libraries (CARL) were ...
Market Cap $1B Current Price $10.93 NASDAQ: CRSP CRISPR Therapeutics Market Cap $4B Current Price $43.84 NASDAQ: GRAL Grail Market Cap $1B Current Price $38.30 NASDAQ: KNSA Kiniksa Pharmaceuticals International, Plc Market Cap $2B Current Price ...